RXi Pharmaceuticals to Present on Retinoblastoma, Vitreoretinopathy at ARVO 2013

RXi Pharmaceuticals, biotechnology company headquartered in Westborough, Mass., has announced it will present its work on the use of its sd-rxRNAs in retinoblastoma and proliferative vitreoretinopathy therapies at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting.

Advertisement
Carrie Pallardy

The presentations are titled “Development of sd-rxRNA for Retinoblastoma Therapy” and “Novel Anti-CTGF RNAi Therapy for Treatment of Proliferative Vitreoretinopathy (PVR) and Other Ocular Disorders.”

More Articles on Ophthalmology:
InSite Vision to Present at ARVO 2013
Glaucoma Management Lens to be Presented at ARVO 2013
Alcon Earns FDA Approval for Fixed-Dose Combination Glaucoma Therapy

Patient perception vs. reality: The role of accreditation in ASC safety

Recommended Whitepaper

Advertisement

Next Up in Ophthalmology

  • Montana physician practice acquired 

    Southlake, Texas-based Retina Consultants of America has acquired Montana Retina Consultants, according to a Feb. 5 news release.  Bozeman-based Montana…

    By: Patsy Newitt

  • Louisiana ophthalmology practice acquired 

    Vision Innovation Partners acquired Ophthalmic Associates of Alexandria (Va.), according to a Feb. 2 press release. Founded in 2010, Ophthalmic…

    By: Patsy Newitt

  • American Board of Ophthalmology names CEO

    The American Board of Ophthalmology has appointed Steven Gedde, MD, as its next CEO.  Dr. Gedde is an ophthalmologist and…

    By: Cameron Cortigiano
Advertisement

Comments are closed.